Vyant Bio (VYNT) Reports In-Line Q3 EPS; Cash and Cash Equivalents of $23.2M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Vyant Bio (VYNT) Reports In-Line Q3 EPS; Cash and Cash Equivalents of $23.2M

Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates

November 11, 2021 4:00 PM EST

Strategic Highlights

Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bios R&D programs targeting the identification of novel therapeuticsEntered into two new first phase feasibility programs with leading biopharma companies to demonstrate Vyant Bios human-derived discovery platform technology for identifying novel biological targets and novel compoundsCompleted a second large screening of artificial intelligence (AI) -generated novel compounds for Rett Syndrome, in... More